TD Asset Management Inc Sells 51,300 Shares of Ascendis Pharma A/S $ASND

TD Asset Management Inc lowered its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 14.9% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 292,090 shares of the biotechnology company’s stock after selling 51,300 shares during the period. TD Asset Management Inc’s holdings in Ascendis Pharma A/S were worth $50,415,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Compagnie Lombard Odier SCmA purchased a new position in Ascendis Pharma A/S during the 2nd quarter valued at about $39,000. Brooklyn Investment Group increased its holdings in Ascendis Pharma A/S by 332.9% during the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 273 shares during the period. LVW Advisors LLC purchased a new position in Ascendis Pharma A/S during the 2nd quarter valued at about $202,000. Dearborn Partners LLC purchased a new position in Ascendis Pharma A/S during the 1st quarter valued at about $203,000. Finally, New Wave Wealth Advisors LLC purchased a new position in Ascendis Pharma A/S during the 1st quarter valued at about $222,000.

Ascendis Pharma A/S Stock Down 0.8%

ASND stock opened at $207.12 on Thursday. Ascendis Pharma A/S has a twelve month low of $118.03 and a twelve month high of $216.45. The firm has a market cap of $12.78 billion, a PE ratio of -40.14 and a beta of 0.41. The business has a 50 day moving average of $198.44 and a 200 day moving average of $176.71.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. On average, research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ASND has been the topic of a number of research analyst reports. Wedbush boosted their price target on Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an “outperform” rating in a report on Friday, August 8th. JPMorgan Chase & Co. lifted their target price on shares of Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Cowen reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Bank of America lifted their target price on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Finally, Wall Street Zen lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Friday, September 5th. Fifteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $248.29.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.